Physician profile
Wayne J Stuart
NPI 1225192099
$6,258.45
in general payments reported to CMS, 2019-2025
35 companies · $519 in 2025
The $519 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,872 · 2020: $694 · 2021: $880 · 2022: $644 · 2023: $916 · 2024: $733 · 2025: $519.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,168.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,168.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,563.51 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $1,029.08 | 2019-2025 | |
| Glaxosmithkline, LLC. | $792.46 | 2019-2025 | Arexvy, Shingrix, Bexsero |
| Amgen INC. | $359.84 | 2019-2025 | Repatha, Otezla, Otezla |
| Abbvie INC. | $289.34 | 2022-2024 | Vraylar, Qulipta, Ubrelvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $222.18 | 2019-2023 | |
| Astellas Pharma US INC | $218.70 | 2019-2024 | Veozah |
| Takeda Pharmaceuticals U.S.A., INC. | $178.01 | 2019-2021 | |
| Lilly USA, LLC | $157.61 | 2019-2022 | |
| Sumitomo Pharma America, INC. | $140.94 | 2023-2025 | Gemtesa |
| Sanofi-Aventis U.S. LLC | $137.04 | 2019-2021 | |
| Astrazeneca Pharmaceuticals Lp | $135.58 | 2019-2024 | Farxiga |
| Dexcom, INC. | $133.97 | 2020-2025 | Dexcom G6 Transmitter |
| Merck Sharp & Dohme LLC | $105.60 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $103.14 | 2019-2022 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $93.13 | 2021-2025 | Gvoke Hypopen |
| Sunovion Pharmaceuticals INC. | $83.32 | 2021-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $81.21 | 2024-2025 | Caplyta |
| Novartis Pharmaceuticals Corporation | $63.04 | 2019 | |
| Alkermes, INC. | $44.13 | 2022 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $41.67 | 2022 | |
| Medtronic, INC. | $37.39 | 2021 | |
| Mylan Specialty L.P. | $31.23 | 2019-2020 | |
| Inspire Medical Systems, INC. | $30.18 | 2024 | Inspire |
| Bayer Healthcare Pharmaceuticals INC. | $28.22 | 2022-2024 | |
| Allergan, INC. | $24.66 | 2019 | |
| Philips North America LLC | $20.15 | 2024 | (Ck7) Extended Holter |
| Hologic Sales and Service, LLC | $18.64 | 2024 | Aptima |
| Abbott Laboratories | $16.01 | 2019 | |
| Dynavax Technologies Corporation | $14.79 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $14.08 | 2020 | |
| Supernus Pharmaceuticals, INC. | $13.65 | 2021 | |
| Medtronic Vascular, INC. | $12.98 | 2020 | |
| Shire North American Group INC | $11.89 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $11.08 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wayne Stuart listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.